Loading…
Imunon, Inc. is projected to decline to $1.54 by 2027, a -2% move from its current price of $1.58. IMNN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.54 | $1.58 | $1.63 | +0.04% |
| Aug 6 | $1.52 | $1.58 | $1.65 | +0.08% |
| Aug 7 | $1.51 | $1.58 | $1.66 | +0.12% |
| Aug 8 | $1.50 | $1.58 | $1.67 | +0.16% |
| Aug 9 | $1.49 | $1.58 | $1.69 | +0.21% |
| Aug 10 | $1.48 | $1.58 | $1.70 | +0.25% |
| Aug 11 | $1.47 | $1.58 | $1.71 | +0.29% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.47 | $1.58 | $1.71 | +0.29% |
| Week 2 | $1.43 | $1.59 | $1.77 | +0.58% |
| Week 3 | $1.40 | $1.59 | $1.81 | +0.87% |
| Week 4 | $1.38 | $1.60 | $1.86 | +1.16% |
| Week 5 | $1.36 | $1.60 | $1.90 | +1.45% |
| Week 6 | $1.34 | $1.61 | $1.93 | +1.74% |
| Week 7 | $1.32 | $1.61 | $1.97 | +2.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. Its lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.
It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response.
The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.
Imunon, Inc. trades under the symbol IMNN. Its current price is $1.51 and its market capitalization is $6.35M. It is ranked 4982. The stock sits in a micro-cap space with notable volatility and a bearish near-term trajectory according to its technicals.
The 30-day range is $1.27 to $1.79, with RSI14 at 30. Shares trade below the SMA50 of $2.02 and the SMA200 of $3.21, indicating near-term weakness. Near-term support is at $1.59 and resistance at $2.06, with annualized volatility around 50%.
The long-run forecast shows a path from neutral to bullish momentum, with 2026 currently at an average of $1.51 and progressing to a 2030 average of $1.92 and a 2050 average of $4.50, with rising ROIs up to 197.7%. These figures illustrate a potential multi-year upside despite current weaknesses.
A major floor 25.9% below — a decisive break under it would weaken the trend.
The nearest floor, 4.4% below — buyers have tended to step in here.
The nearest ceiling, 30.4% above — a clean break opens room to run.
A major ceiling 103.8% above — clearing it would confirm fresh momentum.
Key IMNN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMNN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.56 | Buy | $1.58 | Sell |
| MA 10 | $1.60 | Sell | $1.63 | Sell |
| MA 20 | $1.78 | Sell | $1.72 | Sell |
| MA 50 | $1.91 | Sell | $1.96 | Sell |
| MA 100 | $2.39 | Sell | $2.39 | Sell |
| MA 200 | $3.10 | Sell | $3.59 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.36 | Neutral |
| Stoch RSI (14) | 42.50 | Neutral |
| CCI (20) | -69.99 | Neutral |
| Williams %R (14) | -82.61 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -17.62 | Sell |
| Bollinger %B (20,2) | 0.26 | Neutral |
| Stochastic %K (14) | 17.39 | Buy |
| TRIX (15) | -0.74 | Sell |
| Awesome (5,34) | -0.25 | Sell |
| Ultimate (7,14,28) | 41.44 | Neutral |
| Momentum (10) | -0.24 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 1.56 | Buy |
| ADX (14) | 32.44 | Sell |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is Bearish today, with RSI14 at 30, suggesting subdued momentum.
The stock trades below the SMA50 ($2.02) and the SMA200 ($3.21), reinforcing a cautious near-term stance. Support is identified at $1.59 and resistance at $2.06, framing a near-term range around the current level.
The 30-day range runs from $1.27 to $1.79, highlighting modest upside room in the near term. Annualized volatility is about 50%, underscoring elevated risk in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.51 | $1.58 | $2.03 | 0% | Neutral | |
| $1.23 | $1.54 | $2.05 | -2% | Neutral | |
| $1.23 | $1.60 | $2.21 | +1% | Neutral | |
| $1.28 | $1.70 | $2.43 | +8% | Neutral | |
| $1.49 | $2.02 | $2.95 | +28% | Bullish | |
| $1.52 | $2.11 | $3.15 | +33% | Bullish | |
| $1.35 | $1.90 | $2.90 | +20% | Bullish | |
| $1.42 | $2.03 | $3.15 | +28% | Bullish | |
| $1.39 | $2.03 | $3.21 | +28% | Bullish | |
| $1.30 | $1.92 | $3.07 | +21% | Bullish | |
| $1.65 | $2.62 | $4.47 | +66% | Bullish | |
| $2.59 | $4.64 | $8.69 | +194% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.51 | $1.58 | $1.84 | +0.00% |
| September 2026 | $1.33 | $1.57 | $1.91 | -0.73% |
| October 2026 | $1.38 | $1.64 | $2.02 | +4.58% |
| November 2026 | $1.36 | $1.63 | $2.03 | -0.35% |
| December 2026 | $1.35 | $1.62 | $2.03 | -0.79% |
Click any year to see its month-by-month IMNN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect IMNN to range from $1.51 to $2.03 through 2026. The $1.58 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The IMNN price prediction for 2027 points to an average of $1.54 (low $1.23, high $2.05) — a potential decline of -2% on today's $1.58. Price action looks broadly range-bound.
In 2028, IMNN is projected to trade between $1.23 and $2.21, averaging $1.60 — a potential gain of +1% from today's $1.58. That is up +4% on the projected 2027 average. A consolidation phase looks the most probable path here.
Imunon, Inc.'s 2029 outlook centres on $1.70, within a $1.28 to $2.43 range. That is up +7% on the projected 2028 average. That marks a +8% change versus current levels. Price action looks broadly range-bound.
By 2030, IMNN could reach as high as $2.95, with a base case around $2.02 and support toward $1.49 — roughly +28% from $1.58. Buyers look set to stay in control over this stretch.
Expect IMNN to range from $1.52 to $3.15 through 2031. The $2.11 average target implies a +33% move from current prices. That is up +4% on the projected 2030 average. Momentum favours further upside here.
The IMNN price prediction for 2032 points to an average of $1.90 (low $1.35, high $2.90) — a potential gain of +20% on today's $1.58. Buyers look set to stay in control over this stretch.
In 2033, IMNN is projected to trade between $1.42 and $3.15, averaging $2.03 — a potential gain of +28% from today's $1.58. That is up +7% on the projected 2032 average. Momentum favours further upside here.
Imunon, Inc.'s 2034 outlook centres on $2.03, within a $1.39 to $3.21 range. That is up 0% on the projected 2033 average. That marks a +28% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, IMNN could reach as high as $3.07, with a base case around $1.92 and support toward $1.30 — roughly +21% from $1.58. Momentum favours further upside here.
Expect IMNN to range from $1.65 to $4.47 through 2040. The $2.62 average target implies a +66% move from current prices. That is up +37% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The IMNN price prediction for 2050 points to an average of $4.64 (low $2.59, high $8.69) — a potential gain of +194% on today's $1.58. Momentum favours further upside here.
Investing $1,000 in IMNN today (≈ 632.911392 IMNN) could be worth
$2,935.65
+$1,935.65 (+194%) by 2050 · US Dollar
Based on the average projected IMNN price of $4.64 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMNNwould be worth at today's price.
$1,000 invested in IMNN on Jul 31, 2025 (≈ 138.721346 IMNN) would be worth
$219.18
-$780.82 (-78.1%) today · 0.22× · US Dollar
Based on a IMNN entry price of $7.21 vs. today's $1.58.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.51 | $1,046.36 | +4.6% |
| 1 month ago | $1.88 | $840.43 | -16.0% |
| 3 months ago | $2.8 | $564.29 | -43.6% |
| 6 months ago | $3.18 | $496.86 | -50.3% |
| 1 year ago | $7.21 | $219.18 | -78.1% |
| All time (5.0y) ago | $209.35 | $7.55 | -99.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMNN forecast.
Our base-case forecast reaches $3.20 around 2050.
Implied market cap at $3.20: $13.45M
In the multi-year forecast, Imunon shows a shift from neutral to bullish sentiment beginning in 2030. The 2026 projection sits at an avg of $1.51 with a max of $1.94 and ROI of 0%, reflecting a neutral stance.
From 2027 to 2029, the forecast remains neutral, with averages around $1.48–$1.66 and ROIs between -1.9% and 9.7%. The trajectory turns bullish in 2030, with an avg of $1.92 and a max of $2.76 and a 27% ROI, followed by continued strength into 2031–2035 as averages rise toward the $2 range and beyond.
Longer-horizon results show meaningful upside: by 2040 the avg is $2.48 with a max of $4.14 and a 64.5% ROI, and by 2050 the avg reaches $4.50 with a max of $8.17 and a 197.7% ROI, all under a bullish sentiment. These forecasts imply substantial growth potential over time, but acknowledge risk and uncertainty inherent in long-range projections.
Tap a question to reveal the answer.
2030 forecast: min $1.43, avg $1.92, max $2.76 with ROI 27% and sentiment BULLISH.
Near term shows BEARISH sentiment and a current price of $1.51 with a 30-day range of $1.27–$1.79. Longer term, forecasts turn bullish from 2030 onward, with 2050 average of $4.50 and ROI up to 197.7%, indicating potential upside but with substantial uncertainty.
Yes. The 2050 forecast lists an average of $4.50 and a max of $8.17, indicating the potential to reach around $4 in the long term, though not guaranteed.
Current price is $1.51 and market cap is $6.35M.
Near-term support is $1.59 and resistance is $2.06.
Imunon, Inc. Community Discussion
0Share your Imunon, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.